61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Novo Nordisk A-S
Closed
Sector Healthcare
108.01 -0.06
Overview
Share price change
24h
Min
107.7
Max
108.95
Income | 7.3B 27B |
|---|---|
Sales | 3.3B 71B |
P/E Sector Avg | 39.59 87.008 |
EPS | 6.12 |
Dividend yield | 1.258 |
Profit margin | 38.285 |
EBITDA | 233M 36B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +36.79 upside |
Dividend yield Sector Avg | 1.26% 2.48% |
|---|
Market Cap | -5.2B 369B |
|---|---|
Previous open | 108.07 |
Previous close | 108.01 |
News Sentiment
By Acuity
7%
93%
4 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Neutral Evidence
Novo Nordisk A-S Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novo Nordisk A-S Forecast
Price Target
By TipRanks
36.79% upside
12 Months Forecast
Average 147.8 USD 36.79%
High 160 USD
Low 122 USD
Based on 7 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.
Sentiment
By Acuity
4 / 392 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novo Nordisk A-S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
